Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $22.09 |
|---|---|
| 52-week range | $16.18 - $45.48 |
| 50-day moving average | $19.38 |
| 200-day moving average | $26.42 |
| Wall St. target price | $25.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.09 from 2022-07-01
| 1 week (2022-06-24) | -2.00% |
|---|---|
| 1 month (2022-06-03) | 14.04% |
| 3 months (2022-04-04) | -0.63% |
| 6 months (2022-01-04) | -19.73% |
| 1 year (2021-07-02) | -18.97% |
|---|---|
| 2 years (2020-06-30) | N/A |
| 3 years (2019-06-30) | N/A |
| 5 years (2017-06-30) | N/A |
Valuing Certara stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Certara's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Certara's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72.8 million.
The EBITDA is a measure of a Certara's overall financial performance and is widely used to measure a its profitability.
To put Certara's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $300.9 million |
|---|---|
| Operating margin TTM | 8.45% |
| Gross profit TTM | $174.5 million |
| Return on assets TTM | 1.15% |
| Return on equity TTM | -1.29% |
| Profit margin | -4.02% |
| Book value | $6.57 |
| Market capitalisation | $3.5 billion |
TTM: trailing 12 months
We're not expecting Certara to pay a dividend over the next 12 months.
You may also wish to consider:
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.